Top Pharmaceutical Companies in Minneapolis, MN (8)
Who We Are Chewy is where pet parents find everything they need for life with pets, from food to fun to pharmacy. We make pet care easier, more informed, and more joyful through fast, reliable delivery and award-winning 24/7 Customer Care, including access to pet health support when it’s needed. Founded in 2011, Chewy combines the convenience of online shopping with...
Chewy's Top Stability & Growth Strengths
Profitability: Margins and earnings are expanding, with Q1 FY2026 adjusted EBITDA up, gross margin at 30.1%, and positive net income. FY2025 also delivered record free cash flow alongside margin expansion.
Customer Loyalty & Retention: Autoship represents a large, recurring base at 84.4% of Q1 FY2026 net sales, growing at a double‑digit pace. Rising net sales per active customer and cross‑category engagement point to stickier spend and retention.
Diversified Revenue Streams: Pet health services are scaling through SmartPak and the Modern Animal acquisition, complementing core e‑commerce with clinics and pharmacy. The Modern Animal deal is expected to add over $125M in annualized run‑rate revenue and expand clinics from 18 to 47, with additional openings planned in FY2026.
Pace® works with organizations of all types, providing the science to ensure our air, water, therapies, and more are safe for use. Learn more about our laboratory services at PACELABS.com.
Pace Labs's Top Stability & Growth Strengths
Strong Market Position & Advantage: Pace is widely characterized as a U.S. leader in environmental testing with standout PFAS credentials, including multi‑method DoD accreditations and repeated industry recognition. Life‑sciences credibility is evidenced by FDA‑inspected sites and Top CDMO recognition, with leadership most pronounced in specific U.S. niches.
Market Expansion: The company has materially expanded its footprint via acquisitions (e.g., Alpha Analytical, ESL, Agra) and site adds, bringing the U.S. network to roughly 125–127 labs and service centers by late 2024. Life‑sciences additions (Curia NJ, Catalent RTP) and new centers and facilities further extend reach and capacity.
Future-Ready Strategy: Capacity investments target high‑growth areas such as sterile fill‑finish, biologics, gene therapy, and advanced PFAS methods, alongside positive FDA inspections and new centers of excellence. Backing for expansions, including a state‑supported buildout, indicates preparation for rising regulated testing and advanced therapy demand.
At Padagis our focus is on health care products that improve people’s lives. We are experts on extended topical products and are strategically investing to expand our #1 position in the extended topical category in the United States. Our team members, numbering more than 1,300 work in a dynamic environment where opportunity is built on a foundation of honesty and...
Vireo Health is a physician-led company dedicated to providing patients with best-in-class cannabis-based products and high quality care
Incisive Surgical, Inc. is a privately-held medical device company established to develop proprietary mechanical surgical solutions for
28bio is a neurotechnology company engineering human brains at-scale exhibiting memory, learning, and cognitive functions. Its Nexon™ platform integrates tissue engineering, neural interfacing, and AI to reverse today’s neurological health crisis by improving the ability to predict which therapies will work in humans. 28bio is committed to advancing ethical standards in the development of brain organoid technology and engineered human...
For over 240 years, Takeda’s propensity to evolve has driven the next generation of innovation, and as a future-focused organization, we’re continuing to drive forward with endurance in our steadfast pursuit to achieve the best outcomes for our patients in a rapidly changing world. We have been preparing for this period of value creation by investing in data, digital and...
Takeda's Top Stability & Growth Strengths
Strong Market Position & Advantage: Takeda is consistently placed among the global top 15–20 by revenue and is a clear category leader in GI/IBD, plasma-derived therapies, and dengue vaccines with broad international authorizations and WHO support. Subcutaneous ENTYVIO and new oncology approvals like FRUZAQLA broaden real‑world use and extend reach.
Profitability: Reported FY2025 operating profit rose 19.3% year over year and EPS nearly doubled despite a slight revenue decline, supported by lower amortization and restructuring expense. Core profitability remained broadly stable as Growth & Launch Products expanded their share.
Future-Ready Strategy: Management is investing through FY2026 to convert a late‑stage pipeline (e.g., oveporexton, rusfertide, zasocitinib) into multiple launches, with Growth & Launch Products prioritized as near‑term engines. A multi‑year transformation and efficiency program targeting significant savings by FY2028 is intended to fund launches and strengthen competitiveness.
